In clinical settings, SGLT-2 inhibitors are employed for the management of T2DM as a second-line therapeutic option subsequent to insufficient glycemic regulation with metformin, or as a primary treatment for individuals at high risk for CVD, HF, or CKD [28,29,30,31]. Here, SLC5A2 is linked to hydrops fetalis.